Lung (extracorporeal CO(2) removal) and renal (continuous renal replacement therapy) support: the role of ultraprotective strategy in Covid 19 and non-Covid 19 ARDS. A case-control study

肺(体外二氧化碳清除)和肾(连续性肾脏替代疗法)支持:超保护策略在新冠肺炎和非新冠肺炎急性呼吸窘迫综合征中的作用。一项病例对照研究

阅读:1

Abstract

BACKGROUND: Preliminary studies suggest that moderate ARDS and acute renal failure might benefit from extracorporeal CO(2) removal (ECCO(2)R) coupled with CRRT. However, evidence is limited and potential for this coupled treatment may need to be explored. The aim of the present study was to evaluate whether a protective driving pressure was obtained applying low-flow ECCO(2-)R plus CRRT in patients affected by moderate ARDS with COVID-19 compared to an historical group without COVID-19. METHODS: A case-control study has been conducted comparing a group of consecutive moderate ARDS patients presenting AKI and affected by COVID-19, who needed low-flow ECCO(2-)R plus CRRT to achieve an ultra-protective ventilatory strategy, with historical group without COVID-19 that matched for clinical presentation and underwent the same ultra-protective treatment. V(T) was set at 6 mL/kg predicted body weight then ECCO(2)R was assessed to facilitate ultra-protective low V(T) ventilation to preserve safe Pplat and low driving pressure. RESULTS: ECCO(2)R+CRRT reduced the driving pressure from 17 (14-18) to 11.5 (10-15) cmH(2)O (p<0.0004) in the fourteen ARDS patients by decreasing V(T) from 6.7 ml/kg PBW (6.1-6.9) to 5.1 (4.2-5.6) after 1 hour (p <0.0001). In the ARDS patients with COVID-19, the driving pressure reduction was more effective from baseline 18 (14-24) cmH(2)O to 11 (10-15) cmH(2)O (p<0.004), compared to the control group from 15 (13-17) to 12(10-16) cmH(2)O (p< 0.03), after one hour. ECCO(2)R+CRRT did not affected 28 days mortality in the two groups, while we observed a shorter duration of mechanical ventilation (19 {7-29} vs 24 {22-38} days; p=0.24) and ICU length of stay (19 {7-29} vs 24 {22-78} days; p=0.25) in moderate ARDS patients with COVID-19 compared to control group. CONCLUSIONS: In moderate ARDS patients with or without COVID-19 disease, ECCO(2)R+CRRT may be and effective supportive treatment to reach protective values of driving pressure unless severe oxygenation defects arise requiring ECMO therapy initiation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。